Sight Sciences, Inc.
SGHTNext catalyst
BS01
Retinitis Pigmentosa
Get an email about SGHT's next catalysts
Track Sight Sciences (SGHT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
BS01 Phase 2 Est. Readout
Primary completion for BS01 trial (NCT04278131) in Retinitis Pigmentosa
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BS01 | Phase 2 | Retinitis Pigmentosa | - | - |
Frequently asked questions
What is in Sight Sciences, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Sight Sciences, Inc.'s (SGHT) pipeline across Phase 2. Its lead program is BS01 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Sight Sciences, Inc.'s next FDA catalyst?→
Sight Sciences, Inc.'s (SGHT) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SGHT biotech catalysts?→
Add SGHT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Sight Sciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.